183-193
Original Article
Further mechanistic unravelling of the influence of the cell cycle effects on the radiosensitising mechanism of vinflunine, in vitro
Cindy Simoens, Bea Pauwels, Jan B. Vermorken, Greet G. O. Pattyn and Hilde A. J. Lambrechts, et al.
195-201
Original Article
Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases
M. Ychou, F. Viret, A. Kramar, F. Desseigne and E. Mitry, et al.
203-208
Original Article
The relative bioavailability of gefitinib administered by granular formulation
Mireille V. Cantarini, Chris J. Bailey, Barbara Collins and Robert P. Smith
209-214
Original Article
Phase II study of rubitecan in recurrent or metastatic head and neck cancer
Francesco Caponigro, Giacomo Cartenì, Jean Pierre Droz, Amalia Milano and Wayne B. Davis, et al.
215-226
Original Article
The depletion of cellular ATP by AG2034 mediates cell death or cytostasis in a hypoxanthine-dependent manner in human prostate cancer cells
Oluwakemi Obajimi and Peter W. Melera
227-233
Original Article
Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial
H. Ian Robins, Anne O’Neill, Mark Gilbert, Mark Olsen and Ronald Sapiente, et al.
235-241
Original Article
Effect of
N
-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models
D. Thomas Dickey, Leslie L. Muldoon, Nancy D. Doolittle, Darryl R. Peterson and Dale F. Kraemer, et al.
243-251
Original Article
A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers
Wei-Peng Yong, Ling-Zhi Wang, Lai-San Tham, Chiung-Ing Wong and Soo-Chin Lee, et al.
253-261
Original Article
Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC)
Fernando Rivera, M. Eugenia Vega-Villegas, Marta López-Brea, Dolores Isla and Marta Mayorga, et al.
263-270
Original Article
Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study
Yeul Hong Kim, Hyun Cheol Chung, Won Ki Kang, Sook Ryun Park and Chul Soo Kim, et al.
271-276
Original Article
Changes of cytokines in cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy
Hidenari Nagai, Daisuke Miyaki, Teppei Matsui, Masahiro Kanayama and Katsuya Higami, et al.
277-284
Original Article
Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study
E. Briasoulis, G. Fountzilas, A. Bamias, M. A. Dimopoulos and N. Xiros, et al.
285-292
Original Article
Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women ≥65 years of age
Raffaele Addeo, Vincenzo Faiola, Rosario Guarrasi, Liliana Montella and Bruno Vincenzi, et al.
293-298
Original Article
Temozolomide in combination with fotemustine in patients with metastatic melanoma
Faruk Tas, Hakan Camlica and Erkan Topuz
299-304
Original Article
Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP
Hye Jin Kang, Won Seog Kim, Cheolwon Suh, Yeon Hee Park and Bong Seog Kim, et al.
305-313
Original Article
Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines
Nasredine Aissat, Christophe Le Tourneau, Aïda Ghoul, Maria Serova and Ivan Bieche, et al.
315-320
Original Article
Extracellular signal-regulated kinase phosphorylation due to menadione-induced arylation mediates growth inhibition of pancreas cancer cells
Shinji Osada, Fumio Sakashita, Yosiki Hosono, Kenichi Nonaka and Yasuharu Tokuyama, et al.
321-329
Original Article
Open AccessErufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs
Michael Fiegl, Lars H. Lindner, Matthias Juergens, Hansjoerg Eibl and Wolfgang Hiddemann, et al.
331-333
Original Article
Syndrome of inappropriate secretion of antidiuretic hormone after chemotherapy with vinorelbine
Hiroaki Kuroda, Masafumi Kawamura, Tai Hato, Kazunori Kamiya and Masahiro Kawakubo, et al.
335
Erratum
Syndrome of inappropriate secretion of antidiuretic hormone after chemotherapy with vinorelbine
Hiroaki Kuroda, Masafumi Kawamura, Tai Hato, Kazunori Kamiya and Masahiro Kawakubo, et al.
337-346
Original Article
Mechanisms of enhanced tumoricidal efficacy of multiple small dosages of ranpirnase, the novel cytotoxic ribonuclease, on lung cancer
Intae Lee and Kuslima Shogen
347-354
Clinical Trial Report
Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma
Saby George, Thomas E. Hutson, Tarek Mekhail, Laura Wood and James Finke, et al.
355-361
Clinical Trial Report
Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis
Ronald J. Bernardi, Lisa Bomgaars, Elizabeth Fox, Frank M. Balis and Merrill J. Egorin, et al.
363-368
Short Communication
Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU)
Jan H. Beumer, Robert A. Parise, Edward M. Newman, James H. Doroshow and Timothy W. Synold, et al.
369-372
Short Communication
Consumption of silibinin, a flavonolignan from milk thistle, and mammary cancer development in the C3(1) SV40 T,t antigen transgenic multiple mammary adenocarcinoma (TAg) mouse
Richard D. Verschoyle, Karen Brown, William P. Steward and Andreas J. Gescher